Artrya Ltd. develops the Salix suite of products to address coronary artery disease (CAD). It uses artificial intelligence (AI) to improve the detection and management of coronary artery disease. The company was founded by John Windsor Barrington and John Konstantopoulos on January 24, 2018 and is headquartered in West Perth, Australia.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company